December 22, 2021

From the Co-Chairs, December 2021

The co-chairs reflect on key 2021 accomplishments, and share their thanks and best wishes for a happy New Year
December 22, 2021

Now Enrolling: EAQ201 to Assess COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST Participation

This observational study aims to assess the effects of the pandemic as a barrier to enrollment in the TMIST breast cancer screening trial
December 22, 2021

ECOG-ACRIN Establishes Genomics Subcommittee

The purpose of this new subcommittee, led by Kristen Spencer, DO, MPH, is to develop molecularly-informed concepts—particularly combination concepts
December 22, 2021

Trial Spotlight: Helena Yu on the EA5182 Trial for Metastatic, EGFR-Mutant Non-Small Cell Lung Cancer

This trial aims to help define the optimal first-line treatment for patients with advanced, EGFR-mutant NSCLC and elucidate mechanisms of resistance to therapy
December 22, 2021

ECOG-ACRIN Research at ASH 2021

Researchers with the Leukemia, Lymphoma, and Myeloma Committees presented a range of findings pertaining to treatments, patient-reported outcomes, and genomics
December 22, 2021

News in Brief, December 2021

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
November 16, 2021

From the Co-Chairs, November 2021

Practice-changing trial results in melanoma; Group and committee leadership updates; remembering a dear colleague and friend
November 16, 2021

Trial Results: ASCO Highlights Practice-Changing Results in Melanoma

The phase III DREAMseq clinical trial provides strong evidence for starting treatment with combination immunotherapy then giving targeted therapy if the disease progresses in patients with BRAF V600 mutant metastatic melanoma
November 16, 2021

Remembering Robert B. Catalano, PharmD

In October, the ECOG-ACRIN Cancer Research Group lost one of its most trusted senior counsellors, Regulatory Officer Robert B. Catalano, PharmD
November 16, 2021

Now Enrolling: EAQ202 to Improve Adolescent and Young Adult Self-Reported Data

This pilot study is determining the feasibility and acceptability for adult and young adult participants patients between the ages of 18 and 39 in ECOG-ACRIN treatment trials to use the National Institutes of Health’s Patient-Reported Outcomes Measurement Information System (PROMIS®)
November 16, 2021

30 Member Networks and Programs Receive Commendations in 2021 for Outstanding Research Performance

In an annual evaluation, 30 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
November 16, 2021

Trial Spotlight: Ravi Amaravadi on the EA6191/BAMM2 Trial for Melanoma

This phase II randomized controlled trial is evaluating the effect of adding hydroxychloroquine to treatment with dabrafenib and trametinib in patients with advanced BRAF mutant melanoma